Be part of the knowledge.™

Oncology and Hematology

1888

LikeLikedUnlike

Episodes 121-135 of 260

Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
MinuteCE®
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
- Luis Paz-Ares, MD, PhD
  Peer
- Helena Yu, MD
  Peer
- Matthew Gubens, MD, MS
  Peer
1.00 program credits
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
MinuteCE®
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
- Luis Paz-Ares, MD, PhD
  Peer
- Helena Yu, MD
  Peer
- Matthew Gubens, MD, MS
  Peer
1.00 program credits
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
MinuteCE®
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
- Luis Paz-Ares, MD, PhD
  Peer
- Helena Yu, MD
  Peer
- Matthew Gubens, MD, MS
  Peer
1.00 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer
- Luis Paz-Ares, MD, PhD
  Peer
- Helena Yu, MD
  Peer
- Matthew Gubens, MD, MS
  Peer
1.00 credits 10 episodes
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
CME/CE
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
- Sagar Lonial, MD, FACP
  Peer
- Meghan Berkenstock, MD
  Peer
- Saad Z. Usmani, MD, MBA, FACP
  Peer
0.50 credits
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CE
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
- Joyce O'Shaughnessy, MD
  Peer
0.25 credits
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
CME/CE
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
- David H. Ilson, MD, PhD
  Peer
- Sunnie Kim, MD
  Peer
1.00 credits
The Evolving Role of MET TKIs in NSCLC
CME/CE
The Evolving Role of MET TKIs in NSCLC
- Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
  Peer
- Jyoti Patel, MD
  Peer
0.75 credits
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
CME/CE
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
- Sara M. Tolaney, MD, MPH
  Peer
0.25 credits
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®
Recent updates from adjuvant trials in HR+/HER2- EBC
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended